Leadership

Jan van de Winkel, Ph.D., became the Executive Director of the Merus Board and Chief Executive Officer in December 2025.

Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. He has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications.

Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University and also holds M.S. and Ph.D. degrees from the University of Nijmegen.

He is a registered manager of Genmab with the Danish Business Authority.

Peter B. Silverman, J.D. has served as the Company’s Chief Operating Officer since January 2023, and our General Counsel since February 2018 and Chief Intellectual Property Officer since February 2017, with prior roles including Head of Utrecht from April 2020 to January 2023.

He is responsible for the Company’s operations, including clinical operations, business strategy, legal and intellectual property, and information technology departments. Prior to joining Merus, Mr. Silverman was a Partner at Kirkland & Ellis LLP, where he represented numerous life sciences companies concerning an array of legal matters and technologies. Mr. Silverman was an associate at Kaye Scholer LLP (now Arnold & Porter Kaye Scholer LLP), and prior to that Mr. Silverman also served as judicial law clerk to U.S. District Court Judge Anne E. Thompson of the District of New Jersey. He holds a J.D. from Fordham University School of Law, graduating magna cum laude and Order of the Coif. He is admitted to practice law in New York. Mr. Silverman also holds a B.A. in biology from the University of Rochester.

Cornelis Adriaan (“John”) de Kruif, Ph.D. has served as our Chief Technology Officer since January 2013 and previously served as our Chief Scientific Officer from April 2007 to January 2013.

His responsibilities include management of antibody discovery, antibody platform technology development, antibody engineering, external collaborations, partnerships management and operational activities. Before joining Merus, from October 2000 to October 2006, he served as a director of antibody discovery for Crucell N.V., a biotechnology company, specializing in vaccines and biopharmaceutical technology. Dr. de Kruif holds a Ph.D., in Antibody Engineering from Utrecht University.

Cecilia (“Cecile”) Anna Wilhelmina Geuijen, Ph.D has served as our Chief Scientific Officer since May 2021.

Her responsibilities include strategic scientific leadership, management of pre-clinical research, external collaborations, partnerships management and operational activities. Before joining Merus in 2009, Dr. Geuijen worked as a senior scientist on the evaluation of new therapeutic targets in oncology at Genmab and the identification of new therapeutic targets in oncology at Crucell. She holds a Ph.D. in Biology from the University of Utrecht and was a Marie Curie Fellow at the Duve Institute in Brussels.

Shannon Campbell has served as our Chief Commercial Officer since February 2022.

She is responsible for the global commercialization strategy and activity at Merus. Ms. Campbell has over 25 years of pharmaceutical commercialization experience across a wide range of geographies, markets and product lifecycles. She’s successfully led 25+ specialty brands, including 11 new chemical entity launches across key markets and regions globally. Ms. Campbell most recently led the U.S. Solid Tumor Franchise at Novartis  Pharmaceuticals Corporation where she was responsible for a broad portfolio of oncology and rare disease products. During her time there, she led diverse teams and drove strong commercial execution including multiple launches that changed the standard of care in breast and targeted lung cancers. Prior to Novartis, Ms. Campbell helped to build, launch and subsequently lead Bayer HealthCare Pharmaceuticals US Oncology Business Unit. Prior to Bayer, she held positions of increasing responsibility at Abbott Labs and the Pharmacia heritage companies (Pharmacia & Upjohn, The Upjohn Company). ). She currently serves on the board of directors of Black Diamond Therapeutics. Ms. Campbell holds a Bachelor of Science degree from Ithaca College, and completed several advanced leadership, strategy and finance programs at the University of Michigan Ross School of Business, IMD, Harvard Business School and Wharton.

Ashley Pereira, Pharm.D. has served as our Senior Vice President of Regulatory Affairs since September 2021.

His responsibilities include overseeing the regulatory strategies and activities that advance the development of our clinical programs and maintaining effective and collaborative working relationships with regulatory authorities worldwide. He brings nearly 20 years of clinical-regulatory drug development experience. Dr. Pereira was most recently the Global Regulatory Sciences Deputy Head for hematology therapeutic at Bristol-Myers Squibb (BMS) where he provided direct oversight to the multiple myeloma and lymphoma regulatory teams. Previously, he held numerous roles with increasing responsibilities at BMS, including supporting the development of OPDIVO® (Nivolumab) as the Global Regulatory Group Leader for the Head & Neck, Gastric, Hepatocellular Carcinoma development teams. Dr. Pereira was also the regulatory head for new oncology assets including major collaborations/partnered assets in late stage development. Dr. Pereira holds a Doctorate of Pharmacy from Philadelphia College of Pharmacy & Science.

Ernesto Wasserman, M.D. has served our company since December 2016, first as our Vice President of Clinical Development and currently as Senior Vice President of Clinical Development since January 2022.

His responsibilities include overseeing the planning and executing of clinical programs from early stage through to potential registration. He has over 20 years of experience in oncology clinical drug development. Prior to joining Merus, Dr. Wasserman held positions of increasing responsibility at Novartis, leading development of early and late stage small molecules and biologics in oncology. Notably, he played a key role in the execution of a pivotal clinical program in metastatic melanoma leading to regulatory approval of Braftovi and Mektovi, and contributing to the clinical strategy for Novartis™ immuno-oncology portfolio. Dr. Wasserman is a board certified oncologist; he received his M.D. from the University of Buenos Aires, completed a fellowship in medical oncology at Hopital Paul Brousse (Paris) and visiting fellowships at Hospital 12 de Octubre (Madrid), Memorial Sloan Kettering (New York), and the National Cancer Center (Japan).

Audrey Bergan has served as our Chief People Officer since November 2024.  She is responsible for overseeing the Global human resource (HR) strategy and management at Merus. Ms. Bergan has over 25 years of attracting, developing, and retaining top talent in the pharmaceutical and biotechnology industries. Prior to joining Merus, she was the Senior Vice President, Chief Human Resources Officer, at ImmunoGen from 2014 through its acquisition by AbbVie in May 2024. At ImmunoGen, Ms. Bergan was responsible for Global HR strategy, including talent acquisition and management, leadership and organizational development,  benefits, compensation and HR systems. Ms. Bergan joined ImmunoGen from Philips where she was the Director of Talent Acquisition, Executive Services Americas.  Previously, she spent eight years at Biogen in multiple talent acquisition leadership roles. Earlier in her career, Ms. Bergan worked for BMS, Cubist, Therion Biologics and Wyeth/Genetics Institute in talent acquisition. Ms. Bergan received a Master of Science in Human Resource Counseling from Northeastern University and a Bachelor of Arts in Psychology from University of Massachusetts Amherst.

Greg D. Perry served as a non-executive director of our board of directors since May 2016 and Vice Chairperson of our board of directors since August 2018. Since June 2023, Mr. Perry has served as our Chief Financial Officer (CFO).

His responsibilities include serving as the Principal Financial Officer, and overseeing the finance and quality functions of our organization. From May 2018 until his retirement in April 2022, Mr. Perry served as the CFO at Finch Therapeutics Group. Mr. Perry served as the Chief Financial and Administrative Officer of Novelion Therapeutics Inc. from November 2016 to December 2017. Prior to Novelion, Mr. Perry was CFO of Aegerion Pharmaceuticals Inc. from July 2015 until its merger with Novelion in November 2016. He has also served as CFO of several additional biotechnology companies, and earlier in his career he held various financial leadership roles within PerkinElmer Inc., Domantis Ltd., Honeywell and General Electric. Mr. Perry currently serves on the board of directors of Kala Pharmaceuticals. Mr. Perry received a B.A. in Economics and Political Science from Amherst College.

Fabian Zohren, M.D., Ph.D. has served as our Chief Medical Officer since July 2024. His responsibilities include leading clinical development at Merus. Dr. Zohren is a proven late-stage clinical development expert and most recently he was Chief Medical Officer at ImmunoGen from November 2023 through its acquisition by AbbVie in May 2024. Prior to ImmunoGen, Dr. Zohren worked at Pfizer from 2017 until 2023 where he most recently served as Global Clinical Development Leader for prostate cancer and DNA repair, a role which included Xtandi® (enzalutamide) and Talzenna® (talazoparib) with oversight of two clinical programs encompassing >8000 treated patients and 8 global phase 3 registrational studies in prostate and breast cancer. Earlier in his career at Pfizer, he was the Senior Medical Director and Global Clinical Leader for prostate cancer and gynecological malignancies. He joined Pfizer from Millennium Pharmaceuticals/Takeda where he was the Senior Medical Director and Early Clinical Development Leader for their Cell Signaling Franchise since 2012. Dr. Zohren received his Medical Degree and Ph.D. from the University of Dusseldorf and was a research scholar at Baylor College of Medicine in the Center for Cell and Gene Therapy.

Anand Mehra, M.D. has served as a non-executive director since August 2015 and as Chairperson of our board of directors effective since June 2020. Dr. Mehra held various positions at Sofinnova Investments (f.k.a. Sofinnova Ventures) from 2007 to January 2020, most recently holding the position of a managing general partner, where he focused on working with entrepreneurs to build drug development companies. He led the firm’s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Inc., Aclaris Therapeutics, Inc. (“Aclaris”), and Spark Therapeutics. Prior to joining Sofinnova, Dr. Mehra worked in J.P. Morgan’s private equity and venture capital group and as a consultant at McKinsey & Company. He currently serves as a member of the board of directors of the publicly held life science company Aclaris. Within the past five years, he also served on the boards of directors of the publicly held life science companies Marinus Pharmaceuticals, Inc., Spark Therapeutics, Inc. and Aerie Pharmaceuticals. Dr. Mehra received a B.A. degree in political philosophy from the University of Virginia and an M.D. degree from Columbia University’s College of Physicians and Surgeons.

Maxine Gowen, Ph.D., has served as a non-­executive director to our board of directors since May 2021. Dr. Gowen was the founding President and Chief Executive Officer of Trevena, Inc. (Trevena), from 2007 to October 2018. Prior to this position, Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of 15 years. As Senior Vice President for the company’s Center of Excellence for Drug Discovery, she developed an innovative new approach to externalizing drug discovery. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in and served on the boards of directors of numerous companies. Dr. Gowen also previously served as Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, where she was responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen currently serves on the boards of directors of publicly held life science companies Aclaris and Passage Bio, and served on the boards of directors of publicly held life science companies Akebia Therapeutics (Akebia) and Trevena until May 2021 and Aceragen, Inc., until August 2023. Dr. Gowen holds a B.Sc. in biochemistry from the University of Bristol, U.K., received a Ph.D. in cell biology from the University of Sheffield, U.K., and received an M.B.A. from the Wharton School of the University of Pennsylvania.

Mr. Mueller joined Genmab in July 2025 as Executive Vice President, General Counsel & Chief Legal Officer, responsible for leading and managing the global legal, intellectual property, corporate governance, and global compliance and risk functions.

Before joining Genmab, Mr. Mueller spent more than 20 years at AstraZeneca, living and working in North America, Europe and Asia. For the last 12 years, he was part of the Legal Senior Management Team, holding roles as the Deputy General Counsel, International and then as the Deputy General Counsel, Corporate. Prior to AstraZeneca, Mr. Mueller worked as a corporate transactions lawyer at a large national Canadian law firm.

Mr. Mueller holds a Bachelor of Commerce specialist degree from the University of Toronto and a Law Degree (LLB) from Queen’s University.

Anthony Pagano became a non-executive director on the Merus Board of Directors in December 2025.

Mr. Pagano joined Genmab in 2007, was appointed Senior Vice President in 2011, and became Executive Vice President and Chief Financial Officer effective March 1, 2020. Prior to joining Genmab, Mr. Pagano served as Corporate Controller and Senior Director of Business Planning at NovaDel Pharma, a publicly traded specialty pharmaceutical company. He began his career at KPMG LLP, where he rose to the position of Manager and provided audit and M&A consulting services to clients ranging from start-ups to Fortune 500 companies across a broad range of industries.

He is a Certified Public Accountant and received a B.S. in Accounting from The College of New Jersey, as well as an M.B.A. from the Stern School of Business at New York University.

Mr. Pagano is also a registered manager of Genmab with the Danish Business Authority.

Martine J. van Vugt, Ph.D. became a non-executive director on the Merus board of directors in December 2025

Dr. van Vugt started her professional career at Genmab in 2001 and was appointed Executive Vice President in 2023 and is currently responsible for Corporate Strategy, Corporate Development, Business Development and Licensing and Alliance Management. She has been active in business development operations since 2011.

From 1998 until joining Genmab in 2001 she studied dendritic cell vaccination therapy as a post-doctoral fellow. Dr. van Vugt holds an M.S. from the University of Wageningen and a Ph.D. from Utrecht University.

Jan van de Winkel, Ph.D., became the Executive Director of the Merus Board and Chief Executive Officer in December 2025.

Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. He has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications.

Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University and also holds M.S. and Ph.D. degrees from the University of Nijmegen.

He is a registered manager of Genmab with the Danish Business Authority.